Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01999842 · ClinicalTrials.gov registry record · Phase 1
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3206641A and GSK3206640A Administered in Adults 18 to 64 Years of Age
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 424
- Enrollment target
NCT01999842 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 424 participants.
The verdict
NCT01999842, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 424 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and immunogenicity of different formulations of GSK Biologicals' H7N9 influenza vaccine in subjects 18 to 64 years of age.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Investigational H7N9 vaccine GSK3206641A
- BIOLOGICAL Investigational H7N9 vaccine GSK3206640A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 424 participants |
| Start Date | 2013-11-25 |
| Est. Completion | 2015-01-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01999842
The ClinicalTrials.gov registry entry for NCT01999842 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 424 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01999842 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01999842 about?
NCT01999842 is a clinical study titled "Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3206641A and GSK3206640A Administered in Adults 18 to 64 Years of Age". The purpose of this study is to evaluate the safety and immunogenicity of different formulations of GSK Biologicals' H7N9 influenza vaccine in subjects 18 to 64 years of age.
What is the current status of trial NCT01999842?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 424 participants. The study started on 2013-11-25. Estimated completion is 2015-01-19.
What interventions are being tested in trial NCT01999842?
The interventions under investigation include: Placebo (BIOLOGICAL), Investigational H7N9 vaccine GSK3206641A (BIOLOGICAL), Investigational H7N9 vaccine GSK3206640A (BIOLOGICAL).
Who is sponsoring clinical trial NCT01999842?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.